Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx Group (MDXG) Share-based Compensation: 2011-2024

Historic Share-based Compensation for Mimedx Group (MDXG) over the last 14 years, with Dec 2024 value amounting to $16.9 million.

  • Mimedx Group's Share-based Compensation rose 29.14% to $4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.6 million, marking a year-over-year increase of 12.03%. This contributed to the annual value of $16.9 million for FY2024, which is 0.15% down from last year.
  • Per Mimedx Group's latest filing, its Share-based Compensation stood at $16.9 million for FY2024, which was down 0.15% from $17.0 million recorded in FY2023.
  • In the past 5 years, Mimedx Group's Share-based Compensation ranged from a high of $17.0 million in FY2023 and a low of $11.3 million during FY2022.
  • Over the past 3 years, Mimedx Group's median Share-based Compensation value was $16.9 million (recorded in 2024), while the average stood at $15.1 million.
  • Per our database at Business Quant, Mimedx Group's Share-based Compensation fell by 19.98% in 2022 and then skyrocketed by 49.71% in 2023.
  • Mimedx Group's Share-based Compensation (Yearly) stood at $15.4 million in 2020, then fell by 7.82% to $14.2 million in 2021, then declined by 19.98% to $11.3 million in 2022, then spiked by 49.71% to $17.0 million in 2023, then decreased by 0.15% to $16.9 million in 2024.